Spatiotemporal heterogeneity in non-small cell lung cancer: A paradigm shift from characterization to dynamic management (Review) [0.03%]
非小细胞肺癌时空异质性：从定性到动态管理的范式转变（综述）
Li Cao,Wei Zhang
Li Cao
Treatment of non-small cell lung cancer (NSCLC) has entered the era of precision medicine, characterized by targeted therapies and immunotherapies. However, tumor heterogeneity across spatial and temporal dimensions remains a central cause ...
Long-term survival with tocilizumab treatment for tislelizumab-related pneumonitis in a patient with non-small cell lung cancer: A case report [0.03%]
托西珠单抗治疗替雷利珠单抗相关肺炎一例患者的长期生存报告
Lan Yu,Qing-Ming Guo,Li Liu et al.
Lan Yu et al.
Tislelizumab, an immune checkpoint inhibitor (ICI) that is approved for the treatment of non-small cell lung cancer (NSCLC), has shown superior overall and progression-free survival benefits compared with chemotherapy in clinical trials. Ho...
Case Reports
Oncology letters. 2026 Jun 11;32(2):344. DOI:10.3892/ol.2026.15699 2026
Erratum: [Corrigendum] Engineered AXL-ECD-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration [0.03%]
AxL/Ecd/fc工程变体消除axl/_gas6相互作用可抑制肿瘤细胞迁移的勘误注释
Yanting Duan,Bo Hu,Chunxia Qiao et al.
Yanting Duan et al.
[This corrects the article DOI: 10.3892/ol.2019.10255.]. Copyright: © 2026 Duan et al.
Published Erratum
Oncology letters. 2026 Jun 11;32(2):343. DOI:10.3892/ol.2026.15698 2026
Evangelia Florou,Paul Ross,Parthi Srinivasan et al.
Evangelia Florou et al.
Metastatic pancreatic cancer carries a poor prognosis, with palliative chemotherapy offering limited survival benefit and conversion to resectability considered rare. The present study reports the case of a 60-year-old woman with pancreatic...
Case Reports
Oncology letters. 2026 Jun 11;32(2):336. DOI:10.3892/ol.2026.15691 2026
Tanshinone IIA suppresses cancer metastasis by modulating tumor cell-platelet-endothelial cell interactions [0.03%]
丹参酮ⅡA通过调节肿瘤细胞-血小板-内皮细胞相互作用抑制癌症转移
Judan Xu,Lin Luo,Feiyang Li et al.
Judan Xu et al.
Hematogenous metastasis is a major cause of cancer-related mortality and depends on coordinated interactions between circulating tumor cells, platelets and vascular endothelial cells. Targeting this metastatic microenvironment represents a ...
RTA-408 induces JNK-dependent apoptosis and autophagy in breast cancer cells [0.03%]
RTA-408诱导乳腺癌细胞JNK依赖性凋亡和自噬
Yu-Jen Chen,Hung-Pei Tsai,Mei-Yin Chen et al.
Yu-Jen Chen et al.
RTA-408 is a synthetic activator of the nuclear factor erythroid 2-related factor 2 pathway with antioxidant and anti-inflammatory act2ivity, but its antitumor effects in breast cancer (BC) have not fully been defined. The present study eva...
Kunlei Tan,Zhijun Han,Yali Zhou et al.
Kunlei Tan et al.
Adrenal lymphoma is a rare clinical entity, classified as either primary adrenal lymphoma (PAL) or secondary adrenal lymphoma. PAL is a highly aggressive malignancy with an extremely low incidence rate. To date,
Case Reports
Oncology letters. 2026 Jun 5;32(2):330. DOI:10.3892/ol.2026.15685 2026
Long survival of PD-L1-positive mediastinal sarcomatoid carcinoma after immunotherapy and anti-angiogenic target therapy: A case report [0.03%]
免疫治疗和抗血管生成靶向治疗后PD-L1阳性纵隔肉瘤样癌长期存活的病例报告
Shuling Wu,Danping Wang,Qiong Fu et al.
Shuling Wu et al.
Mediastinal sarcomatoid carcinoma (SC) is rare and is often associated with poor survival outcomes. At present, there have been no investigations into the use of immunotherapy and anti-angiogenic target therapy to treat mediastinal SC. In t...
Case Reports
Oncology letters. 2026 Jun 11;32(2):335. DOI:10.3892/ol.2026.15690 2026
Primary malignant melanoma of the common bile duct: An unexpected finding at pancreaticoduodenectomy: A case report [0.03%]
胆总管原发恶性黑色素瘤：胰十二指肠切除术中的意外发现：病例报告
Evangelia Florou,Hamad Almakinzy,Yoh Zen et al.
Evangelia Florou et al.
Bile duct tumours are most commonly primary cholangiocarcinomas, and upfront surgical resection is often undertaken with curative intent, as preoperative histological confirmation is not routinely required. Melanoma, an aggressive malignanc...
Case Reports
Oncology letters. 2026 Jun 11;32(2):334. DOI:10.3892/ol.2026.15689 2026
Construction and validation of a predictive model of pathological complete response combined with MRI and tumor indicators for HER2-positive breast cancer after neoadjuvant targeted therapy [0.03%]
联合MRI和肿瘤标志物构建HER2阳性乳腺癌新辅助靶向治疗后病理性完全缓解的预测模型及验证
Keying Zhu,Zeying Li,Jiaqian Liao et al.
Keying Zhu et al.
Accurate models for predicting pathological complete response (pCR) after neoadjuvant therapy (NAT) are increasingly needed in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). In the present study, ...